Federal Register / Vol. 74, No. 67 / Thursday, April 9, 2009 / Notices 16235 

Drug Schedule 

3,4-Methylenedioxyamphetamine 

(7400).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (7405).

I 

4-Methoxyamphetamine (7411) ... I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

N-Benzylpiperazine (7493) ........... I 

Acetyldihydrocodeine (9051) ........ I 

Dihydromorphine (9145) ............... I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Pholcodine (9314) ........................ I 

Tilidine (9750) ............................... I 

3-Methylfentanyl (9813) ................ I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to import 

analytical reference standards for 

distribution to its customers for research 

and analytical purposes. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act (21 U.S.C. 

952(a)(2)(B)) may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

being sent via regular or express mail 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODL, 8701 

Morrissette Drive, Springfield, VA 

22152; and must be filed no later than 

May 11, 2009. 

This procedure is to be conducted 

simultaneously with and independent 

of the procedures described in 21 CFR 

1301.34(b), (c), (d), (e) and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substances in schedule I 

or II are and will continue to be required 

to demonstrate to the Deputy Assistant 

Administrator, Office of Diversion 

Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e) and (f) are 

satisfied. 

Dated: April 1, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–8088 Filed 4–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 26, 2008 

and published in the Federal Register 

on December 5, 2008, (73 FR 74095), GE 

Healthcare, 3350 North Ridge Avenue, 

Arlington Heights, Illinois 60004–1412, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of Cocaine (9041), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture a 

radioactive product used in diagnostic 

imaging in the diagnosis of Parkinson’s 

Disease and for manufacture in bulk for 

investigational new drug (IND) 

submission and clinical trials. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of GE 

Healthcare to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated GE 

Healthcare to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: April 1, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–8089 Filed 4–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances Notice of Registration 

By Notice dated November 26, 2008 

and published in the Federal Register 

on December 5, 2008, (73 FR 74196), ISP 

Freetown Fine Chemicals, 238 South 

Main Street, Assonet, Massachusetts 

02702, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

2,5-Dimethoxyamphetamine 

(7396).

I 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Phenylacetone (8501) .................. II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

The company plans to manufacture 

Phenylacetone to be used in the 

manufacture of Amphetamine for 

distribution to its customers. The bulk 

2,5-Dimethoxyamphetamine will be 

used for conversion into non-controlled 

substances. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of ISP 

Freetown Fine Chemicals to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated ISP Freetown Fine 

Chemicals to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. § 823, 


dwashington3 on PROD1PC60 with NOTICES